• DOI:10.1213/ANE.0b013e3181eac011
• Corpus ID: 39217801

Repinotan, a Selective 5-HT1A-R-Agonist, Antagonizes Morphine-Induced Ventilatory Depression in Anesthetized Rats

@article{Guenther2010RepinotanAS,
  title={Repinotan, a Selective 5-HT1A-R-Agonist, Antagonizes Morphine-Induced Ventilatory Depression in Anesthetized Rats},
  author={Ulf Guenther and Hermann Wrigge and Nils Ulrich Theuerkauf and Michael Boettcher and Georg Wensing and Joerg Zinserling and Christian Putensen and Andreas Hoeft},
  journal={Anesthesia \& Analgesia},
  year={2010},
  volume={111},
  pages={901–907}
}

• U. Guenther, H. Wrigge, +5 authors A. Hoeft
• Published 1 August 2010
• Biology, Medicine
• Anesthesia & Analgesia

BACKGROUND:Spontaneous breathing during mechanical ventilation improves arterial oxygenation and cardiovascular function, but is depressed by opioids during critical care. Opioid-induced ventilatory depression was shown to be counteracted in anesthetized rats by serotonin(1A)-receptor (5-HT1A-R)-agonist 8-OH-DPAT, which cannot be applied to humans. Repinotan hydrochloride is a selective 5-HT1A-R-agonist already investigated in humans, but the effects on ventilation and nociception are unknown. In this study, we sought to establish (a) the effects of repinotan on spontaneous breathing and nociception, and (b) the interaction with the standard opiate morphine. METHODS:The dose-dependent effects of repinotan, given alone or in combination with morphine, on spontaneous minute ventilation (MV) and nociceptive tail-flick reflex latencies (TFLs) were measured simultaneously in spontaneously breathing anesthetized rats. An additional series with NaCl 0.9% and the 5-HT1A-R-antagonist WAY 100 135 served as controls. RESULTS:(a) Repinotan dose-dependently activated spontaneous breathing (MV, mean [95% confidence interval]; 53% [29%–77%]) of pretreatment level) and suppressed nociception (TLF, 91% maximum possible effect [68%–114%]) with higher doses of repinotan (2–200 &mgr;g/kg). On the contrary, nociception was enhanced with a small dose of repinotan (0.2 &mgr;g/kg; TFL, −47% maximum possible effect [−95% to 2%]). Effects were prevented by 5-HT1A-antagonist WAY 100 135. (B) Morphine-induced depression of ventilation (MV, −72% [−100% to −44%]) was reversed by repinotan (20 &mgr;g/kg), which returned spontaneous ventilation to pretreatment levels (MV, 18% [−40% to 77%]). The morphine-induced complete depression of nociception was sustained throughout repinotan and NaCl 0.9% administration. Despite a mild decrease in mean arterial blood pressure, there were no serious cardiovascular side effects from repinotan. CONCLUSIONS:The 5-HT1A-R-agonist repinotan activates spontaneous breathing in anesthetized rats even in morphine-induced ventilatory depression. The potency of 5-HT1A-R-agonists to stimulate spontaneous breathing and their antinociceptive effects should be researched further.